Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Business Exposures
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
Johnson & Johnson Strikes $1.7B Deal To Acquire Heart-Tech Innovator V-Wave
Via Benzinga
Exposures Product Safety
Tickers AZN JNJ
BMW Recalls Nearly 721K Vehicles In US Over Short Circuit Worries: Both Gas And Hybrid Electric Cars Affected
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
Tickers BMWYY
AlgoDx Receives FDA Clearance for Sepsis Detection Software
Via EZ Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Bob Marley Film Where Michael Gandolfini Plays Iconic publicist Howard Bloom Goes #1 on Paramount Plus
Via AB Newswire
Topics Product Recall
Exposures Legal Product Safety
Psychedelics And Mental Health: FDA Stalls, But States Forge Ahead
Via Benzinga
Exposures Product Safety
FDA Rejects MDMA for Mental Health Treatment After Identifying Flawed Study Data
Via PRLog
Topics Death
Exposures Death Product Safety
Tickers NYT
Austin singer-songwriter Nathan Hamilton returns with Not One Among Us, Oct. 11. A beautiful collab with Japanese musician/producer Shotaro Miyamoto
Via PRLog
Topics Product Recall Religion
Exposures Legal Product Safety Religion
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
Via Benzinga
Topics ETFs
Exposures COVID-19 Product Safety
Tickers BBP BNTX FDL FTXH
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
Via MarketBeat
Exposures COVID-19 Product Safety
Tickers BNTX MRK MRNA NVAX
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder
Via PressReach
Exposures Product Safety
Tickers ALZN
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Reports on Status of Lead Drug Candidate Designed to Treat Concussion
Via Investor Brand Network
Exposures Product Safety
Tickers OGEN
FDA Allows Resumption Of BioNTech/MediLink Therapeutics Partnered Phase 1 Study For Cancer Drug With Lower Dose
Via Benzinga
Exposures Product Safety
Tickers BNTX
United Health Products Submits Response Letter to FDA
Via NewMediaWire
Exposures Product Safety
Tickers UEEC
FDA Rejects MDMA for Mental Health Treatment After Identifying Flawed Study Data
Via Press Release Distribution Service
Exposures Product Safety
Lykos Therapeutics Strategic Reorganization Following FDA's Decision Rejecting MDMA For PTSD Treatment
Via Benzinga
Exposures Product Safety
Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study
Via Benzinga
Exposures Product Safety
Tickers INCY
FDA Approves AstraZeneca's Blockbuster Cancer Drug, Imfinzi, In Combination With Chemo For Non-Small Cell Lung Cancer
Via Benzinga
Exposures Product Safety
Tickers AZN
From Detroit Dreams to Hollywood Realities: Anise Fuller’s Journey with Walk By Faith Productions
Via Small Business Trendsetters
Topics Product Recall
Exposures Legal Product Safety
Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday?
Via Benzinga
Exposures Product Safety
Tickers RHHBY TPST
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q2 2024 Financial Report, Operational Update
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Tickers BEAT
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Reports on Q2 2024 Financial Results, Business Highlights
Via Investor Brand Network
Exposures Product Safety
Tickers LGVN
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Publishes Q2 2024 Results
Via Investor Brand Network
Exposures Product Safety
Tickers CNSP
FDA Rejects MDMA Therapy Application, Calls for More Research
Via Investor Brand Network
Exposures Product Safety
FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication
Via Benzinga
Exposures Product Safety
Tickers INCY SNDX
FDA Approves Gilead's Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal
Via Benzinga
Exposures Product Safety
Tickers GILD
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Tickers ABVC
“Explosive Growth Stocks: Innovations, Strategy, Earners Unlock Prime Potential CXAI, OGEN, PRSO, INBS, KAVL”
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Tickers CXAI INBS OGEN PRSO
Don't Promote Copycat Weight-Loss Drugs Amid Improved Supply, Eli Lilly Asks Doctors, FDA Evaluates
Via Benzinga
Exposures Product Safety
Tickers LLY NVO
Substantial Funding, Debt Resolution, HOPE Dividend, Successful Clinical Trial Towards Accelerated Drug Approval for Bipolar Depression: Nasdaq: NRXP
Via PRLog
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Tickers NRXP
Kaya Holdings Advocates For Psilocybin As FDA Rejects MDMA For PTSD Treatment
Via Benzinga
Exposures Product Safety
Tickers KAYS
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.